Ironwood Pharmaceuticals’ Stock Plummets Following Layoffs and FDA Setback for Apraglutide

Ironwood Pharmaceuticals , apraglutide , short bowel syndrome (SBS) , Phase III trial , layoffs , FDA regulatory hurdle , stock plunge , strategic alternatives , Goldman Sachs , biotechnology

Navigating Challenges: Keros and Tempest Aim to Stabilize and Strategize for Growth

Keros Therapeutics , Strategic alternatives , Financial challenges , Biopharmaceutical sector , Stockholder rights plan , Clinical trials , Tempest Therapeutics , Corporate restructuring , Biotechnology investments

U.S. Congressional Report Calls for $15 Billion to Bolster Biotech Leadership Amid Rising Chinese Competition

U.S. Biotechnology Advantage, China Biotech Competition, National Security Commission on Emerging Biotechnology, Biotechnology Investment, Biomanufacturing Strategy, U.S.-China Tech Rivalry, Bioeconomy

Rocket Pharmaceuticals Expands Leadership with J&J and AstraZeneca Alumni to Strengthen Gene Therapy Commercialization

Rocket Pharmaceuticals, gene therapy, commercial leadership, Sarbani Chaudhuri, Johnson & Johnson, AstraZeneca, commercial launch, gene therapy market, rare diseases, biotechnology, Kresladi, RP-L102.

Callio Therapeutics Debuts with $187M to Develop Next-Generation Multi-Payload ADCs for Cancer

Multi-payload ADCs, antibody-drug conjugates, oncology, HER2-targeted therapy, dual-payload technology, cancer treatment, biotechnology startup

Allakos Discontinues AK006 Development, Cuts 75% of Workforce Amid Strategic Restructuring

Allakos, AK006, workforce reduction, strategic alternatives, Phase 1 trial failure, chronic spontaneous urticaria (CSU), biotechnology, restructuring costs.